We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Aveanna (AVAH): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Aveanna Healthcare (AVAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.13 per share, reflecting an increase of 30% compared to the same period last year. Revenues are forecasted to be $616.44 million, representing a year-over-year increase of 10.2%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Aveanna metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenue- PDS' will reach $511.81 million. The estimate suggests a change of +11.3% year over year.
It is projected by analysts that the 'Revenue- MS' will reach $44.82 million. The estimate indicates a change of +5.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- HHH' should come in at $61.57 million. The estimate points to a change of +8.5% from the year-ago quarter.
The consensus estimate for 'Hours - PDS' stands at 11748 hours. Compared to the present estimate, the company reported 10887 hours in the same quarter last year.
The collective assessment of analysts points to an estimated 'Revenue rate - MS' of $490.58 . The estimate compares to the year-ago value of $477.45 .
Analysts forecast 'Unique patients served (UPS) - MS' to reach 92 . Compared to the current estimate, the company reported 89 in the same quarter of the previous year.
The average prediction of analysts places 'Revenue rate - PDS' at $43.56 . Compared to the present estimate, the company reported $42.25 in the same quarter last year.
Over the past month, shares of Aveanna have returned +8.4% versus the Zacks S&P 500 composite's +9.1% change. Currently, AVAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q1 Potential of Aveanna (AVAH): Exploring Wall Street Estimates for Key Metrics
In its upcoming report, Aveanna Healthcare (AVAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.13 per share, reflecting an increase of 30% compared to the same period last year. Revenues are forecasted to be $616.44 million, representing a year-over-year increase of 10.2%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Aveanna metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenue- PDS' will reach $511.81 million. The estimate suggests a change of +11.3% year over year.
It is projected by analysts that the 'Revenue- MS' will reach $44.82 million. The estimate indicates a change of +5.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- HHH' should come in at $61.57 million. The estimate points to a change of +8.5% from the year-ago quarter.
The consensus estimate for 'Hours - PDS' stands at 11748 hours. Compared to the present estimate, the company reported 10887 hours in the same quarter last year.
The collective assessment of analysts points to an estimated 'Revenue rate - MS' of $490.58 . The estimate compares to the year-ago value of $477.45 .
Analysts forecast 'Unique patients served (UPS) - MS' to reach 92 . Compared to the current estimate, the company reported 89 in the same quarter of the previous year.
The average prediction of analysts places 'Revenue rate - PDS' at $43.56 . Compared to the present estimate, the company reported $42.25 in the same quarter last year.
View all Key Company Metrics for Aveanna here>>>Over the past month, shares of Aveanna have returned +8.4% versus the Zacks S&P 500 composite's +9.1% change. Currently, AVAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .